Dalia Bejjani, MD

Clinical Assistant Professor

20072013
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Bio

Dr. Bejjani is board certified in Infectious Diseases and Internal Medicine. She maintains membership in the Infectious Diseases Society of America and has held academic appointments since 2007. Dr. Bejjani has numerous publications and national/international abstracts and presentations. She currently practices at the Seton Trinity Facility.

Fingerprint Dive into the research topics where Dalia Bejjani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

rosiglitazone Medicine & Life Sciences
HIV Medicine & Life Sciences
Carotid Intima-Media Thickness Medicine & Life Sciences
Placebos Medicine & Life Sciences
Reverse Transcriptase Inhibitors Medicine & Life Sciences
Peroxidase Medicine & Life Sciences
Thymidine Medicine & Life Sciences
Peroxisome Proliferator-Activated Receptors Medicine & Life Sciences

Research Output 2007 2013

13 Citations (Scopus)

A case of endocarditis caused by lactococcus garvieae and suggested methods for identification

Navas, M. E., Hall, G. & El Bejjani, D., Jun 1 2013, In : Journal of Clinical Microbiology. 51, 6, p. 1990-1992 3 p.

Research output: Contribution to journalArticle

Lactococcus
Endocarditis
Fishes
Gram-Positive Cocci
Heart Valves
4 Citations (Scopus)

Changes in inflammation, oxidative stress, mitochondrial DNA content after rosiglitazone in HIV lipoatrophy

Tungsiripat, M., El-Bejjani, D., Rizk, N., Hu, B., Ross, A. C., Walker, U. A., Lebrecht, D., Milne, G., Storer, N. & McComsey, G. A., Oct 1 2012, In : Journal of AIDS and Clinical Research. 3, 8

Research output: Contribution to journalArticle

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Mitochondrial DNA
Oxidative Stress
Tumor Necrosis Factor Receptors
9 Citations (Scopus)

Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo

Tungsiripat, M., Bejjani, D., Rizk, N., Dogra, V., O'Riordan, M. A., Ross, A. C., Hileman, C., Storer, N., Harrill, D. & McComsey, G. A., Mar 1 2011, In : AIDS Research and Human Retroviruses. 27, 3, p. 295-302 8 p.

Research output: Contribution to journalArticle

rosiglitazone
Carotid Intima-Media Thickness
Placebos
HIV
Vascular Cell Adhesion Molecule-1
27 Citations (Scopus)

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens

Tungsiripat, M., Bejjani, D. E., Rizk, N., O'Riordan, M. A., Ross, A. C., Hileman, C., Storer, N., Harrill, D. & McComsey, G. A., Jun 1 2010, In : AIDS. 24, 9, p. 1291-1298 8 p.

Research output: Contribution to journalArticle

rosiglitazone
Reverse Transcriptase Inhibitors
Thymidine
Placebos
Peroxisome Proliferator-Activated Receptors
171 Citations (Scopus)

Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-infected Patients Receiving Antiretroviral Therapy

Ross, A. C., Rizk, N., O'Riordan, M. A., Dogra, V., El-Bejjani, D., Storer, N., Harrill, D., Tungsiripat, M., Adell, J. & McComsey, G. A., Oct 1 2009, In : Clinical Infectious Diseases. 49, 7, p. 1119-1127 9 p.

Research output: Contribution to journalArticle

Carotid Intima-Media Thickness
HIV
Internal Carotid Artery
Vascular Cell Adhesion Molecule-1
Therapeutics